文献速递血管炎

蛋白酶3基因Val119Ile纯合多态性与ANCA相关性血管炎复发风险

Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism.
PubMed 文献 · RMD Open · 2023-01-01

在利妥昔单抗治疗ANCA相关性血管炎试验的188例患者中进行PRTN3基因SNP rs351111检测,64例PR3-AAV患者中PRTN3-Ile119纯合者18个月严重复发频率显著高于PRTN3-Val119纯合者(46.2% vs 19.6%,p=0.048),多因素分析显示PRTN3-Ile119纯合为严重复发主要预测因子(HR 4.67,95%CI 1.16至18.86,p=0.030)。

要点

  • PR3-AAV患者中PRTN3-Ile119纯合者18个月严重复发频率显著高于PRTN3-Val119纯合者。
  • 多因素分析显示PRTN3-Ile119纯合为严重复发主要预测因子(HR 4.67,95%CI 1.16至18.86)。
  • DNA检测与mRNA表达在86例双方法分析患者中一致率为100%。

核心结论

  • 在PR3-AAV患者中,PRTN3-Val119Ile多态性纯合状态似乎与较高的严重复发频率相关。
  • 需要进一步研究以更好地理解该观察与严重复发风险的关联。

研究设计与样本

  • 对纳入利妥昔单抗治疗ANCA相关性血管炎试验的PR3-AAV患者进行PRTN3基因SNP rs351111(chr.19:844020,c.355G>A)DNA变异检测,评估等位基因频率。
  • 随后进行RNA-seq变异检测以表征mRNA表达,并比较PRTN3-Ile119纯合与PRTN3-Val119纯合患者的临床结局。

主要发现

  • 188例患者有全血样本用于DNA检测,其中75例PR3-AAV携带等位变异:62例为PRTN3-Val119Ile杂合,13例为PRTN3-Ile119纯合。
  • 89例患者有RNA-seq数据,32例PR3-AAV检出对应等位变异的mRNA:25例为PRTN3-Val119Ile杂合,7例为PRTN3-Ile119纯合。
  • 86例同时用两种方法分析的患者中,DNA检测结果与mRNA表达一致率为100%。
  • 比较64例PR3-AAV患者临床结局:51例为PRTN3-Val119纯合,13例为PRTN3-Ile119纯合。
  • PRTN3-Ile119纯合者18个月严重复发频率显著高于PRTN3-Val119纯合者(46.2% vs 19.6%,p=0.048)。

关键数值与推荐

  • 多因素分析确定PR3-Ile119纯合为严重复发的主要预测因子(HR 4.67,95%CI 1.16至18.86,p=0.030)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究以更好地理解该观察与严重复发风险的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The frequency of proteinase 3 gene (PRTN3) polymorphisms in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is not fully characterised. We hypothesise that the presence of a PRTN3 gene polymorphism (single nucleotide polymorphism (SNP) rs351111) is relevant for clinical outcomes. METHODS: DNA variant calling for SNP rs351111 (chr.19:844020, c.355G>A) in PRTN3 gene assessed the allelic frequency in patients with PR3-AAV included in the Rituximab in ANCA-Associated Vasculitis trial. This was followed by RNA-seq variant calling to characterise the mRNA expression. We compared clinical outcomes between patients homozygous for PRTN3-Ile119 or PRTN3-Val119. RESULTS: Whole blood samples for DNA calling were available in 188 patients. 75 patients with PR3-AAV had the allelic variant: 62 heterozygous PRTN3-Val119Ile and 13 homozygous for PRTN3-Ile119. RNA-seq was available for 89 patients and mRNA corresponding to the allelic variant was found in 32 patients with PR3-AAV: 25 heterozygous PRTN3-Val119Ile and 7 homozygous for PRTN3-Ile119. The agreement between the DNA calling results and mRNA expression of the 86 patients analysed by both methods was 100%. We compared the clinical outcomes of 64 patients with PR3-AAV: 51 homozygous for PRTN3-Val119 and 13 homozygous for PRTN3-Ile119. The frequency of severe flares at 18 months in homozygous PRTN3-Ile119 was significantly higher when compared with homozygous PRTN3-Val119 (46.2% vs 19.6%, p=0.048). Multivariate analysis identified homozygous PR3-Ile119 as main predictor of severe relapse (HR 4.67, 95% CI 1.16 to 18.86, p=0.030). CONCLUSION: In patients with PR3-AAV, homozygosity for PRTN3-Val119Ile polymorphism appears associated with higher frequency of severe relapse. Further studies are necessary to better understand the association of this observation with the risk of severe relapse.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Casal Moura M, Deng Z, Brooks SR, et al. Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism. RMD Open. 2023. PMID: 36990659. doi:10.1136/rmdopen-2022-002935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。